2023
Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas
Ly C, Blaha O, Wei W, Galan A, Kluger H, Ariyan S, Olino K, Clune J. Predictive accuracy of elevated mitotic rate on lymph node positivity and recurrence in thin melanomas. Frontiers In Oncology 2023, 12: 1077226. PMID: 36686728, PMCID: PMC9853390, DOI: 10.3389/fonc.2022.1077226.Peer-Reviewed Original ResearchMelanoma-specific mortalityElevated mitotic rateLymph node positivityMitoses/Mitotic rateT2 tumorsNode positivityThin melanomasSentinel lymph node positivityImportant prognostic factorSingle academic centerPrimary cutaneous melanomaLow mitotic ratePositive SLNNon-ulcerated lesionsSLN biopsyT4 tumorsPatient demographicsPrognostic factorsSLN positivityRetrospective reviewTumor characteristicsBreslow thicknessCutaneous melanomaT category
2022
Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis
Srivastava A, Patel H, Koehne E, Gupta G, Drachtman R, Pierorazio P, Bagrodia A, Elsamra S, Kim I, Ghodoussipour S, Singer E, Jang T, Patel H, Barone J. Survival of nonseminomatous germ cell tumors in pediatric patients and young adults – A stage group stratified analysis. Urologic Oncology Seminars And Original Investigations 2022, 40: 169.e1-169.e12. PMID: 35144865, PMCID: PMC8960351, DOI: 10.1016/j.urolonc.2021.12.012.Peer-Reviewed Original ResearchConceptsNonseminomatous germ cell tumorsCancer-specific survivalGerm cell tumorsCell tumorsStage groupPediatric patientsAdolescent patientsYoung adultsStage IAdvanced nonseminomatous germ cell tumorsSurvival analysisAge groupsWorse cancer-specific survivalCox proportional hazards modelTesticular germ cell tumorsEnd Results (SEER) databaseExcellent survival outcomesStage III tumorsExcellent oncologic outcomesImportant prognostic factorKaplan-Meier curvesCommon solid malignancyProportional hazards modelNSGCT patientsOncologic outcomes
2019
Assessment of obesity prevalence and validity of obesity diagnoses coded in claims data for selected surgical populations
Ammann EM, Kalsekar I, Yoo A, Scamuffa R, Hsiao CW, Stokes AC, Morton JM, Johnston SS. Assessment of obesity prevalence and validity of obesity diagnoses coded in claims data for selected surgical populations. Medicine 2019, 98: e16438. PMID: 31335698, PMCID: PMC6709187, DOI: 10.1097/md.0000000000016438.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedArthroplasty, Replacement, KneeBariatric SurgeryBody Mass IndexCatheter AblationClinical CodingElectronic Health RecordsFemaleHerniorrhaphyHumansMaleMiddle AgedObesityOutcome Assessment, Health CarePatient SelectionPrevalencePrognosisReproducibility of ResultsRetrospective StudiesUnited StatesConceptsBody mass indexPositive predictive valueBariatric surgeryDiagnosis codesElectronic health recordsSurgical populationClaims dataHernia repairObesity diagnosisPrognostic factorsSurgical outcomesInterpretation of studiesCardiac ablationPatient body mass indexMeasured body mass indexHigh positive predictive valueImportant prognostic factorType of surgeryAdministrative healthcare dataAdministrative claims dataFalse positive patientsPatient ageMass indexPatient selectionIndex procedure
2018
Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade
Metzger‐Filho O, Ferreira AR, Jeselsohn R, Barry WT, Dillon DA, Brock JE, Vaz‐Luis I, Hughes ME, Winer EP, Lin NU. Mixed Invasive Ductal and Lobular Carcinoma of the Breast: Prognosis and the Importance of Histologic Grade. The Oncologist 2018, 24: e441-e449. PMID: 30518616, PMCID: PMC6656459, DOI: 10.1634/theoncologist.2018-0363.Peer-Reviewed Original ResearchConceptsInvasive lobular carcinomaDisease-free survivalHistologic gradeLobular carcinomaPostmenopausal womenSystemic therapyBetter prognosisAromatase inhibitorsPrognostic powerDisease-free survival advantageEarly-stage breast cancerFavorable disease-free survivalCox proportional hazards modelAdjuvant aromatase inhibitorsBaseline clinicopathologic characteristicsDetailed clinical databaseHER2-negative diseaseRetrospective cohort studyImportant prognostic factorKaplan-Meier methodProportional hazards modelIntermediate histologic gradeDistinct disease subtypesCohort studyOverall prognosisPrognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes
Liao G, Hsu H, Chu C, Hong Z, Fu C, Chou Y, Golshan M, Dai M, Chen T, De-Chian C, Tsai W, Pan C, Hsu K, Kao E, Hsu Y, Chang T, Yu J. Prognostic role of lymphovascular invasion and lymph node status among breast cancer subtypes. Journal Of Medical Sciences 2018, 38: 54-61. DOI: 10.4103/jmedsci.jmedsci_105_17.Peer-Reviewed Original ResearchRecurrent-free survivalBreast cancer subtypesLymph node statusLymphovascular invasionOverall survivalImportant prognostic factorLymph nodesPrognostic factorsHuman Investigation CommitteeLuminal HER2 subtypeNode statusHER2 subtypeBreast cancerSignificant differencesCancer subtypesLymph node involvementYear of diagnosisInstitutional review board approvalKaplan-Meier analysisTriple-negative subtypeMultivariate survival analysisCox proportional hazardsDate of deathReview board approvalSignificant independent relationship
2017
Identifying Metastases-related Information from Pathology Reports of Lung Cancer Patients.
Soysal E, Warner J, Denny J, Xu H. Identifying Metastases-related Information from Pathology Reports of Lung Cancer Patients. AMIA Joint Summits On Translational Science Proceedings 2017, 2017: 268-277. PMID: 28815141, PMCID: PMC5543353.Peer-Reviewed Original ResearchPathology reportsSpecimen siteImportant prognostic factorLung cancer patientsMetastatic patternPrognostic factorsClinical courseHistological typeCancer patientsMetastasis sitesMetastatic statusCancer recurrenceCancer metastasisMetastasisTumor metastasisPatientsStatus indicatorsReportStatusRecurrenceValidation of the ureteral diameter ratio for predicting early spontaneous resolution of primary vesicoureteral reflux
Arlen AM, Kirsch AJ, Leong T, Cooper CS. Validation of the ureteral diameter ratio for predicting early spontaneous resolution of primary vesicoureteral reflux. Journal Of Pediatric Urology 2017, 13: 383.e1-383.e6. PMID: 28256423, DOI: 10.1016/j.jpurol.2017.01.012.Peer-Reviewed Original ResearchConceptsPrimary vesicoureteral refluxUreteral diameter ratioVesicoureteral refluxReflux gradeSpontaneous resolutionVUR gradeMultivariable modelUreteral diameterDistal ureteral diameter ratioGrade of VURLargest ureteral diameterPersistent vesicoureteral refluxVesicoureteral reflux gradeGrade of refluxImportant prognostic factorSpontaneous resolution rateValuable prognostic informationL3 vertebral bodyUnit increaseExternal validation studyHighest likelihood ratioVUR timingPersistent diseasePrimary outcomePrognostic factors
2016
Inter-rater reliability of distal ureteral diameter ratio compared to grade of VUR
Swanton A, Arlen A, Alexander S, Kieran K, Storm D, Cooper C. Inter-rater reliability of distal ureteral diameter ratio compared to grade of VUR. Journal Of Pediatric Urology 2016, 13: 207.e1-207.e5. PMID: 28089295, DOI: 10.1016/j.jpurol.2016.10.021.Peer-Reviewed Original ResearchConceptsUreteral diameter ratioDistal ureteral diameter ratioVesicoureteral refluxVUR gradeInter-rater reliabilityReflux gradePediatric urologistsGrade of VURGrading of VURLargest ureteral diameterHigh grade refluxImportant prognostic factorPrimary vesicoureteral refluxConfidence intervalsSignificant inter-rater variabilityGood inter-rater reliabilityPrognostic factorsClinical courseClinical outcomesPredictive factorsRenal unitsUreteral diameterInter-rater agreementSpontaneous resolutionBlinded fashionLung Cancer Staging and Prognosis
Woodard GA, Jones KD, Jablons DM. Lung Cancer Staging and Prognosis. Cancer Treatment And Research 2016, 170: 47-75. PMID: 27535389, DOI: 10.1007/978-3-319-40389-2_3.Peer-Reviewed Original ResearchConceptsTNM stageLung Cancer Lung Cancer Staging ProjectCancer TNM staging systemLung Cancer Staging ProjectSurvival estimatesIndividualized survival estimatesNew immunotherapy drugsStage IA diseaseStage IV diseaseImportant prognostic factorTNM staging systemPoor prognostic indicatorMolecular prognostic markersSignificant survival differenceTumor histologic gradeLung cancer stagingMolecular tumor profilingGenetic tumor analysisIA diseaseTNM groupingsOverall survivalPerformance statusMolecular prognosticationPD-L1Prognostic factorsClinical implications for imaging of vascular invasion in hepatocellular carcinoma
Baheti AD, Dunham GM, Ingraham CR, Moshiri M, Lall C, Park JO, Li D, Katz DS, Madoff DC, Bhargava P. Clinical implications for imaging of vascular invasion in hepatocellular carcinoma. Abdominal Radiology 2016, 41: 1800-1810. PMID: 27142384, DOI: 10.1007/s00261-016-0763-2.Peer-Reviewed Original ResearchConceptsHepatocellular carcinomaVascular invasionManagement of HCCImportant prognostic factorLimited treatment optionsPromising treatment strategyPrognostic factorsTumor thrombusCancer mortalityTreatment optionsPatient managementTreatment strategiesInterventional radiologistsClinical implicationsLargest causeComprehensive updateCarcinomaInvasionRadiologistsThrombusMajor roleMortalityDiagnosisTrends in malignant intraductal papillary mucinous neoplasm in US adults from 1990 to 2010: a SEER database analysis
McCarty TR, Njei B. Trends in malignant intraductal papillary mucinous neoplasm in US adults from 1990 to 2010: a SEER database analysis. Gastroenterology Report 2016, 4: 113-118. PMID: 26818977, PMCID: PMC4863191, DOI: 10.1093/gastro/gov066.Peer-Reviewed Original ResearchMalignant intraductal papillary mucinous neoplasmIntraductal papillary mucinous neoplasmAge-adjusted incidencePapillary mucinous neoplasmLong-term survivalMedian survivalMucinous neoplasmsUtilization of surgeryEnd Results (SEER) databaseOverall median survivalImportant prognostic factorSEER database analysisProportional hazards regressionNumber of patientsAdenoma-carcinoma sequenceIndependent mortality factorsPerformance of surgeryPrognostic factorsSurgical treatmentRadiographic evidenceEligible casesHazards regressionResults databaseDecreased riskMalignant potential
2014
Molecular Imaging of Tumor Hypoxia with Positron Emission Tomography
Kelada OJ, Carlson DJ. Molecular Imaging of Tumor Hypoxia with Positron Emission Tomography. Radiation Research 2014, 181: 335-349. PMID: 24673257, PMCID: PMC5555673, DOI: 10.1667/rr13590.1.Peer-Reviewed Original ResearchConceptsTumor hypoxiaOncology communityTumor hypoxic volumeImportant prognostic factorOverall treatment responseRisk of metastasisTypes of tumorsEmission Tomography ImagingPositron emission tomography (PET) imagingClinical oncology communityPositron emission tomographyConventional cancer therapiesMagnitude of hypoxiaPrognostic factorsCancer patientsTreatment responseField of PETChemotherapy resistanceEmission tomographyClinical settingRadiolabelled agentsCancer typesPatientsHypoxia tracerHypoxiaRisk Adjustment of Ischemic Stroke Outcomes for Comparing Hospital Performance
Katzan IL, Spertus J, Bettger JP, Bravata DM, Reeves MJ, Smith EE, Bushnell C, Higashida RT, Hinchey JA, Holloway RG, Howard G, King RB, Krumholz HM, Lutz BJ, Yeh RW. Risk Adjustment of Ischemic Stroke Outcomes for Comparing Hospital Performance. Stroke 2014, 45: 918-944. PMID: 24457296, DOI: 10.1161/01.str.0000441948.35804.77.Peer-Reviewed Original ResearchMeSH KeywordsAmerican Heart AssociationBrain IschemiaHospitalsHumansModels, OrganizationalOutcome Assessment, Health CarePatient ReadmissionPredictive Value of TestsPrognosisQuality of Health CareRecovery of FunctionReproducibility of ResultsRisk AdjustmentSample SizeStrokeTreatment OutcomeUnited StatesConceptsIschemic stroke outcomeRisk-adjustment modelsStroke severityStroke outcomeStroke careOutcome measuresHospital levelRisk-adjusted outcome comparisonsRisk adjustmentHospital-level outcomesHospital performanceVascular risk factorsImportant prognostic factorIschemic stroke careIndividual patient levelStroke severity measuresRisk-adjusted modelsHospital-level performanceQuality of strokeComparison of qualityIschemic strokePrognostic factorsComorbid conditionsFunctional outcomeMajor disability
2013
The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer
Sperduto PW, Kased N, Roberge D, Chao ST, Shanley R, Luo X, Sneed PK, Suh J, Weil RJ, Jensen AW, Brown PD, Shih HA, Kirkpatrick J, Gaspar LE, Fiveash JB, Chiang V, Knisely JP, Sperduto CM, Lin N, Mehta M. The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. Journal Of Neuro-Oncology 2013, 112: 467-472. PMID: 23462853, DOI: 10.1007/s11060-013-1083-9.Peer-Reviewed Original ResearchConceptsNumber of BMBrain metastasesGraded Prognostic AssessmentPrimary diagnosisPrognostic factorsTumor subtypesMedian survivalBreast cancerDiagnosis-Specific Graded Prognostic AssessmentDevelopment of BMMulti-institutional retrospective databaseImportant prognostic factorIndependent prognostic factorBreast cancer patientsER/PRBreast cancer subtypesBreast-GPAProspective studyCancer patientsLuminal ALuminal BRetrospective databaseHER2 subtypeBrain MRIPrognostic assessmentA model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed.
Halabi S, Lin C, Small E, Armstrong A, Kaplan E, Petrylak D, Sternberg C, Shen L, Oudard S, De Bono J, Sartor A. A model for predicting overall survival in men with metastatic castrate-resistant prostate cancer (CRPC) for whom first-line chemotherapy failed. Journal Of Clinical Oncology 2013, 31: 24-24. DOI: 10.1200/jco.2013.31.6_suppl.24.Peer-Reviewed Original ResearchFirst-line chemotherapyCastrate-resistant prostate cancerMedian overall survivalOverall survivalLow-risk groupRisk groupsPrognostic modelHazard ratioMetastatic castrate-resistant prostate cancerECOG performance statusPhase III trialsImportant prognostic factorProstate-specific antigenTime-dependent areaTime-dependent AUCDocetaxel useMCRPC settingMeasurable diseaseIII trialsPerformance statusProgressive diseaseVisceral diseasePrognostic factorsHormonal useClinical trials
2011
Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer
Chun YS, Cooper HS, Cohen SJ, Konski A, Burtness B, Denlinger CS, Astsaturov I, Hall MJ, Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3601-3607. PMID: 21947697, DOI: 10.1245/s10434-011-2086-4.Peer-Reviewed Original ResearchConceptsPathologic response ratePathologic responsePreoperative therapyPancreatic adenocarcinomaResponse rateComplete pathologic response rateMajor pathologic response rateMajor pathologic responseNegative lymph nodesImportant prognostic factorMinority of patientsSmaller tumor sizeMedian survival rateR0 resectionConsecutive patientsPancreatic headPartial responsePrognostic factorsImproved survivalLymph nodesTumor sizeHistopathologic examinationMinor responsePancreatic cancerTherapy occurs
2009
Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements
Lanoy E, May M, Mocroft A, Phillip A, Justice A, Chêne G, Furrer H, Sterling T, Monforte A, Force L, Gill J, Harris R, Hogg R, Rockstroh J, Saag M, Khaykin P, de Wolf F, Sterne J, Costagliola D. Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements. AIDS 2009, 23: 2199-2208. PMID: 19779320, PMCID: PMC3122149, DOI: 10.1097/qad.0b013e3283305a00.Peer-Reviewed Original ResearchConceptsCombination antiretroviral therapyCD4 cell countHIV-1-infected patientsHIV-1 RNAViral loadCART initiationCell countStart of cARTHIV-1 RNA measurementsART Cohort CollaborationMedian CD4 cellPredictors of AIDSRates of AIDSImportant prognostic factorPrognosis of patientsCohort CollaborationSubsequent AIDSAntiretroviral therapyHIV cohortCD4 cellsPrognostic factorsPrognostic importanceCopies/PatientsAIDSPreoperative Cardiac Risk Index Predicts Long-term Mortality and Health Status
Hoeks SE, Reimer W, van Gestel YR, Smolderen KG, Verhagen H, van Domburg RT, van Urk H, Poldermans D. Preoperative Cardiac Risk Index Predicts Long-term Mortality and Health Status. The American Journal Of Medicine 2009, 122: 559-565. PMID: 19376487, DOI: 10.1016/j.amjmed.2008.10.041.Peer-Reviewed Original ResearchMeSH KeywordsAgedCardiovascular DiseasesCerebrovascular DisordersConfidence IntervalsData CollectionDiabetes Mellitus, Type 1FemaleFollow-Up StudiesHealth StatusHealth SurveysHumansMaleMiddle AgedNetherlandsOdds RatioPerioperative CarePeripheral Vascular DiseasesPredictive Value of TestsPreoperative CarePrognosisRegression AnalysisRenal InsufficiencyRisk AdjustmentRisk AssessmentRisk FactorsSurveys and QuestionnairesSurvival AnalysisVascular Surgical ProceduresConceptsPeripheral Artery QuestionnaireImpaired health statusPeripheral arterial disease patientsArterial disease patientsInsulin-dependent diabetesLate mortalityPrognostic factorsHealth statusVascular surgeryRenal insufficiencyCerebrovascular diseaseDisease patientsDisease-specific Peripheral Artery QuestionnaireLong-term health statusPAQ summary scorePerioperative cardiac riskCardiac risk factorsCardiac Risk IndexLong-term mortalityPeripheral arterial diseaseImportant prognostic factorIndependent prognostic factorIschemic heart diseaseMultivariable regression analysisRisk index score
2004
Current treatment options for endometrial cancer
Santin AD, Bellone S, O’Brien T, Pecorelli S, Cannon MJ, Roman JJ. Current treatment options for endometrial cancer. Expert Review Of Anticancer Therapy 2004, 4: 679-689. PMID: 15270671, DOI: 10.1586/14737140.4.4.679.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, HormonalAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCell DifferentiationCisplatinDoxorubicinEndometrial NeoplasmsFemaleHumansHysterectomyNeoplasm InvasivenessNeoplasm Recurrence, LocalOvariectomyPaclitaxelPrognosisRadiotherapy, AdjuvantReceptor, ErbB-2Risk FactorsSurvival AnalysisTrastuzumabConceptsEndometrial cancerMyometrial invasionStage I endometrial cancer patientsLow-toxicity regimenEndometrial cancer patientsLymph node dissectionRecurrent endometrial cancerTotal abdominal hysterectomyClear cell histologyCornerstone of treatmentPostoperative radiation therapyImportant prognostic factorCurrent treatment optionsCombination of cisplatinFemale genital tractAttractive therapeutic strategyMajority of casesType II receptorExtrapelvic recurrenceAbdominal hysterectomyNode dissectionPelvic radiotherapyPelvic recurrenceSystemic chemotherapyVaginal bleedingBrain metastases
Omuro AM, Abrey LE. Brain metastases. Current Neurology And Neuroscience Reports 2004, 4: 205-210. PMID: 15102346, DOI: 10.1007/s11910-004-0040-6.Peer-Reviewed Original ResearchConceptsWhole brain radiotherapyBrain metastasesBrain radiotherapyPerformance statusPoor prognosisSystemic diseaseFocal therapyAggressive focal therapiesGood performance statusImportant prognostic factorTreatment of recurrenceLong-term survivorsStandard of careTypes of tumorsPrognostic factorsTreatment of cancerPatient populationTreatment decisionsCognitive deteriorationLocal controlMetastasisPatientsPrognosisRadiotherapyTherapy
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply